Recent submissions

  • Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients 

    Hedayat-Husseyin, S (2020-09-30)
    MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ...
  • The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. 

    Chong, IY; Starling, N; Rust, A; Alexander, J; Aronson, L; Llorca-Cardenosa, M; Chauhan, R; Chaudry, A; Kumar, S; Fenwick, K; Assiotis, I; Matthews, N; Begum, R; Wotherspoon, A; Terlizzo, M; Watkins, D; Chau, I; Lord, CJ; Haider, S; Rao, S; Cunningham, D (2021-01-09)
    1.<h4>Background</h4>The application of massively parallel sequencing has led to the identification of aberrant druggable pathways and somatic mutations within therapeutically relevant genes in gastro-oesophageal cancer. ...
  • Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. 

    Finn, RS; Rugo, HS; Gelmon, KA; Cristofanilli, M; Colleoni, M; Loi, S; Schnell, P; Lu, DR; Theall, KP; Mori, A; Gauthier, E; Bananis, E; Turner, NC; Diéras, V (2021-01-23)
    <h4>Background</h4>Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure.< ...
  • Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. 

    Pal Choudhury, P; Brook, MN; Hurson, AN; Lee, A; Mulder, CV; Coulson, P; Schoemaker, MJ; Jones, ME; Swerdlow, AJ; Chatterjee, N; Antoniou, AC; Garcia-Closas, M (2021-02-15)
    <h4>Background</h4>The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) and the Tyrer-Cuzick breast cancer risk prediction models are commonly used in clinical practice and have ...
  • Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells. 

    Parkhitko, AA; Singh, A; Hsieh, S; Hu, Y; Binari, R; Lord, CJ; Hannenhalli, S; Ryan, CJ; Perrimon, N (2021-02-16)
    The RB1 tumor suppressor is recurrently mutated in a variety of cancers including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate cancers, and osteosarcomas. Finding new synthetic lethal ...
  • 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. 

    Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; Wai, PT; Maguire, SL; Barker, HE; Morrison, E; Kriplani, D; Yu, L; Gibson, A; Falgari, G; Brennan, K; Farnie, G; Buus, R; Marlow, R; Novo, D; Knight, E; Guppy, N; Kolarevic, D; Susnjar, S; Milijic, NM; Naidoo, K; Gazinska, P; Roxanis, I; Pancholi, S; Martin, L-A; Holgersen, EM; Cheang, MCU; Noor, F; Postel-Vinay, S; Quinn, G; McDade, S; Krasny, L; Huang, P; Daley, F; Wallberg, F; Choudhary, JS; Haider, S; Tutt, AN; Natrajan, R (2021-01-28)
    Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...
  • Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study. 

    Au, L; Fendler, A; Boos, LA; Byrnes, F; Shepherd, S; Nicholson, E; Kumar, S; Yousaf, N; Wilkinson, K; Swerdlow, A; Harvey, R; Kassiotis, G; Wilkinson, R; Larkin, J; Turajlic, S (AMER ASSOC CANCER RESEARCH, 2020-03-01)
  • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. 

    Coignard, J; Lush, M; Beesley, J; O'Mara, TA; Dennis, J; Tyrer, JP; Barnes, DR; McGuffog, L; Leslie, G; Bolla, MK; Adank, MA; Agata, S; Ahearn, T; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Arnold, N; Aronson, KJ; Arun, BK; Augustinsson, A; Azzollini, J; Barrowdale, D; Baynes, C; Becher, H; Bermisheva, M; Bernstein, L; Białkowska, K; Blomqvist, C; Bojesen, SE; Bonanni, B; Borg, A; Brauch, H; Brenner, H; Burwinkel, B; Buys, SS; Caldés, T; Caligo, MA; Campa, D; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Conroy, DM; Czene, K; Daly, MB; Devilee, P; Diez, O; Ding, YC; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Dwek, M; Eccles, DM; Eliassen, AH; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Flyger, H; Fostira, F; Friedman, E; Fritschi, L; Frost, D; Gago-Dominguez, M; Gapstur, SM; Garber, J; Garcia-Barberan, V; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Gayther, SA; Gehrig, A; Georgoulias, V; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; He, W; Hogervorst, FBL; Hollestelle, A; Hopper, JL; Horcasitas, DJ; Hulick, PJ; Hunter, DJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Jager, A; Jakubowska, A; James, PA; Jensen, UB; John, EM; Jones, ME; Kaaks, R; Kapoor, PM; Karlan, BY; Keeman, R; Khusnutdinova, E; Kiiski, JI; Ko, Y-D; Kosma, V-M; Kraft, P; Kurian, AW; Laitman, Y; Lambrechts, D; Le Marchand, L; Lester, J; Lesueur, F; Lindstrom, T; Lopez-Fernández, A; Loud, JT; Luccarini, C; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mebirouk, N; Meindl, A; Miller, A; Milne, RL; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nielsen, FC; O'Brien, KM; Olopade, OI; Olson, JE; Olsson, H; Osorio, A; Ottini, L; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peshkin, B; Peterlongo, P; Peto, J; Pharoah, PDP; Phillips, K-A; Polley, EC; Poppe, B; Presneau, N; Pujana, MA; Punie, K; Radice, P; Rantala, J; Rashid, MU; Rennert, G; Rennert, HS; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sandler, DP; Santella, R; Scheuner, MT; Schmidt, MK; Schmidt, G; Scott, C; Sharma, P; Soucy, P; Southey, MC; Spinelli, JJ; Steinsnyder, Z; Stone, J; Stoppa-Lyonnet, D; Swerdlow, A; Tamimi, RM; Tapper, WJ; Taylor, JA; Terry, MB; Teulé, A; Thull, DL; Tischkowitz, M; Toland, AE; Torres, D; Trainer, AH; Truong, T; Tung, N; Vachon, CM; Vega, A; Vijai, J; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wolk, A; Yadav, S; Yang, XR; Yannoukakos, D; Zheng, W; Ziogas, A; Zorn, KK; Park, SK; Thomassen, M; Offit, K; Schmutzler, RK; Couch, FJ; Simard, J; Chenevix-Trench, G; Easton, DF; Andrieu, N; Antoniou, AC (2021-02-17)
    Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in ...
  • Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1. 

    Sflomos, G; Battista, L; Aouad, P; De Martino, F; Scabia, V; Stravodimou, A; Ayyanan, A; Ifticene-Treboux, A; RLS; Bucher, P; Fiche, M; Ambrosini, G; Brisken, C
    Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E-cadherin. It has clinical features distinct from other estrogen receptor-positive ...
  • Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. 

    Stevenson, J; Barrow-McGee, R; Yu, L; Paul, A; Mansfield, D; Owen, J; Woodman, N; Natrajan, R; Haider, S; Gillett, C; Tutt, A; Pinder, SE; Choudary, J; Naidoo, K (2021-03-05)
    In breast cancer (BC), detecting low volumes of axillary lymph node (ALN) metastasis pre-operatively is difficult and novel biomarkers are needed. We recently showed that patient-derived ALNs can be sustained ex-vivo using ...
  • Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. 

    Battisti, NML; Liposits, G; De Glas, NA; Gomes, F; Baldini, C; Mohile, S (2020-07-28)
    <h4>Purpose of review</h4>Decision-making for systemic treatments in older patients with cancer is difficult because of concerns for decreased organ function, risk of toxicity, limited life expectancy due to comorbidities ...
  • Perspectives on geriatric oncology research presented at the 2019 San Antonio Breast Cancer Symposium. 

    Battisti, NML; Lok, WCW; Subbiah, I; Okonji, D; Desideri, I; Soto-Perez-De-Celis, E
  • Embracing the complexity: Older adults with cancer-related cognitive decline-A Young International Society of Geriatric Oncology position paper. 

    Pergolotti, M; Battisti, NML; Padgett, L; Sleight, AG; Abdallah, M; Newman, R; Van Dyk, K; Covington, KR; Williams, GR; van den Bos, F; Pollock, Y; Salerno, EA; Magnuson, A; Gattás-Vernaglia, IF; Ahles, TA
    Cancer-related cognitive decline (CRCD) may have particularly significant consequences for older adults, impacting their functional and physical abilities, level of independence, ability to make decisions, treatment ...
  • Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. 

    Gomes, F; Wong, M; Battisti, NML; Kordbacheh, T; Kiderlen, M; Greystoke, A; Luciani, A
    Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer ...
  • Perspectives on Geriatric Oncology Research Presented at the 2020 San Antonio Breast Cancer Symposium 

    Hill, A; Chan, W-L; Shih, Y-Y; Tiwari, A; Monteiro, AR; Mackenzie, P; Magnuson, A; Battisti, NML; Sedrak, MS
  • Caring for older patients with cancer during the COVID-19 pandemic: A Young International Society of Geriatric Oncology (SIOG) global perspective. 

    Desideri, I; Pilleron, S; Battisti, NML; Gomes, F; de Glas, N; Neuendorff, NR; Liposits, G; Paredero-Pérez, I; Lok, WCW; Loh, KP; DuMontier, C; Mian, H; Soto-Perez-de-Celis, E
    The ongoing coronavirus disease 2019 (COVID-19) pandemic has affected millions of people in over 180 territories, causing a significant impact on healthcare systems globally. Older adults, as well as people living with ...
  • Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. 

    Battisti, NML; Reed, MWR; Herbert, E; Morgan, JL; Collins, KA; Ward, SE; Holmes, GR; Bradburn, M; Walters, SJ; Burton, M; Lifford, K; Edwards, A; Robinson, TG; Martin, C; Chater, T; Pemberton, KJ; Shrestha, A; Brennan, A; Cheung, KL; Todd, A; Audisio, RA; Wright, J; Simcock, R; Green, T; Revell, D; Gath, J; Horgan, K; Holcombe, C; Winter, MC; Naik, J; Parmeshwar, R; Gosney, MA; Hatton, MQ; Thompson, AM; Wyld, L; Ring, A; Age Gap TMG
    <h4>Introduction</h4>Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older ...
  • Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group. 

    Nielsen, TO; Leung, SCY; Rimm, DL; Dodson, A; Acs, B; Badve, S; Denkert, C; Ellis, MJ; Fineberg, S; Flowers, M; Kreipe, HH; Laenkholm, A-V; Pan, H; Penault-Llorca, FM; Polley, M-Y; Salgado, R; Smith, IE; Sugie, T; Bartlett, JMS; McShane, LM; Dowsett, M; Hayes, DF (2020-12-28)
    Ki67 immunohistochemistry, commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 Working Group (IKWG) consensus ...
  • Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. 

    Hewitt, G; Borel, V; Segura-Bayona, S; Takaki, T; Ruis, P; Bellelli, R; Lehmann, LC; Sommerova, L; Vancevska, A; Tomas-Loba, A; Zhu, K; Cooper, C; Fugger, K; Patel, H; Goldstone, R; Schneider-Luftman, D; Herbert, E; Stamp, G; Brough, R; Pettitt, S; Lord, CJ; West, SC; Ahel, I; Ahel, D; Chapman, JR; Deindl, S; Boulton, SJ (2020-12-15)
    Chromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions. ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function in DNA repair ...

View more